A5082250124- Cancer Genomics and Diagnostics
- Pancreatic and Hepatic Oncology Research
- Cancer Research and Treatments
- Radiomics and Machine Learning in Medical Imaging
- MicroRNA in disease regulation
- Cancer Cells and Metastasis
- Prostate Cancer Treatment and Research
- Medical Imaging Techniques and Applications
- RNA modifications and cancer
- Lung Cancer Treatments and Mutations
- Peptidase Inhibition and Analysis
- Single-cell and spatial transcriptomics
- RNA Interference and Gene Delivery
- Cancer-related molecular mechanisms research
- PARP inhibition in cancer therapy
- Liver physiology and pathology
- Cancer Immunotherapy and Biomarkers
- Lung Cancer Research Studies
- Cell Image Analysis Techniques
- Colorectal Cancer Treatments and Studies
- Cancer Mechanisms and Therapy
- Advanced Drug Delivery Systems
- Advanced Breast Cancer Therapies
- PI3K/AKT/mTOR signaling in cancer
- Radiopharmaceutical Chemistry and Applications
Hospital Universitario 12 De Octubre
2022-2024
Research Institute Hospital 12 de Octubre
2024
Spanish National Cancer Research Centre
2013-2023
Hospital Universitario Virgen de la Arrixaca
2021-2023
Centro de Investigación del Cáncer
2012-2023
Instituto Maimónides de Investigación Biomédica de Córdoba
2022
Highlight Therapeutics (Spain)
2018-2020
Instituto de Investigación Biomédica de Málaga
2020
Cancer Genetics (United States)
2014
Sidney Kimmel Cancer Center
2014
Nab-paclitaxel and gemcitabine have demonstrated a survival benefit over alone in advanced pancreatic cancer (PDA). This study aimed to investigate the clinical, biological, imaging effects of regimen patients with operable PDA. Patients PDA received two cycles nab-paclitaxel before surgical resection. FDG-PET CA19.9 tumour marker levels were used measure clinical activity. Effects on stroma determined by endoscopic ultrasound (EUS) elastography. The collagen content architecture as well...
Highlights•CDK4/6 inhibitors should be applied after and not before cytotoxic chemotherapy•CDK4/6 prevent DNA repair mitotic poisons DNA-damaging agents•Inhibiting CDK4/6 results in an RB1-dependent repression of the DNA-repair machinery•CDK4/6 PARP cooperate preventing tumor cell proliferationSummaryInhibition cell-cycle kinases CDK4 CDK6 is now part standard treatment advanced breast cancer. inhibitors, however, are expected to with or antimitotic chemotherapies as former entry, thus...
BackgroundAlthough germline BRCA mutations have been associated with adverse outcomes in prostate cancer (PC), understanding of the association between somatic/germline alterations homologous recombination repair (HRR) genes and treatment metastatic castration-resistant PC (mCRPC) is limited.The aim this study was to investigate prevalence HRR alterations, particularly BRCA1/2, patients initiating first-line (1L) mCRPC androgen receptor signalling inhibitors (ARSi) or taxanes.Patients...
Current technology permits an unbiased massive analysis of somatic genetic alterations from tumor DNA as well the generation individualized mouse xenografts (Avatar models). This work aimed to evaluate our experience integrating these two strategies personalize treatment patients with cancer.We performed whole-exome sequencing 25 advanced solid tumors identify putatively actionable tumor-specific genomic alterations. Avatar models were used in vivo platform test proposed...
Abstract Purpose: MET exon 14 deletion (METex14 del) mutations represent a novel class of non–small cell lung cancer (NSCLC) driver mutations. We evaluated glesatinib, spectrum-selective inhibitor exhibiting type II binding mode, in METex14 del–positive nonclinical models and NSCLC patients assessed its ability to overcome resistance I inhibitors. Experimental Design: As most inhibitors clinical development bind the active site with we investigated mechanisms acquired each utilizing vitro...
Abstract Purpose: nab-Paclitaxel plus gemcitabine was superior to alone for patients with metastatic pancreatic cancer (MPC) in the phase III MPACT trial. This study evaluated association of secreted protein acidic and rich cysteine (SPARC) levels efficacy as an exploratory endpoint. Experimental Design: Patients previously untreated MPC (N = 861) received nab-paclitaxel or alone. Baseline SPARC level measured tumor stroma epithelia (archival biopsies) plasma. Experiments were performed...
K-RAS –mutated lung adenocarcinomas depend on ERBB signaling, and pan-ERBB inhibitors impair K-RAS–driven tumorigenesis.
Poly I:C is a powerful immune adjuvant as result of its agonist activities on TLR-3, MDA5 and RIG-I. BO-112 nanoplexed formulation complexed with polyethylenimine that causes tumor cell apoptosis showing immunogenic death features which upon intratumoral release results in more prominent infiltration by T lymphocytes. Intratumoral treatment subcutaneous tumors derived from MC38, 4 T1 B16-F10 leads to remarkable local disease control dependent type-1 interferon gamma-interferon. Some degree...
Interferon-independent MHC class I induction restores T cell immunity.
The tumor microenvironment plays a key role in cancer development and progression is involved resistance to chemo- immunotherapy. Cancer-associated fibroblast expressing fibroblast-activating protein α (FAPα) one of the predominant stroma cell types immunotherapy.We generated OMTX705, novel antibody-drug conjugate from humanized anti-FAP antibody linked new cytolysin. Here, we studied its antineoplastic activity vitro preclinical mouse models alone combination with chemotherapy as well...
Intratumoral BO-112 combined with systemic anti–PD-1 shows immunotherapeutic potential to control tumors in patients primarily refractory anti–PD-1.
Large-sequencing cancer genome projects have shown that tumors thousands of molecular alterations and their frequency is highly heterogeneous. In such scenarios, physicians oncologists routinely face lists genomic where only a minority them are relevant biomarkers to drive clinical decision-making. For this reason, the medical community agrees on urgent need methodologies establish relevance tumor alterations, assisting in profile interpretation, and, more importantly, prioritize those could...
Purpose: Since drug responses vary between patients, it is crucial to develop pre-clinical or co-clinical strategies that forecast patient response. In this study, we tested whether RNA-based therapeutics were suitable for personalized medicine by using patient-derived-organoid (PDO) and patient-derived-xenograft (PDX) models.Experimental Design: We performed microRNA (miRNA) profiling of PDX samples determine the status miRNA deregulation in individual pancreatic ductal adenocarcinoma...
// Rodrigo A. Toledo 1,4,* , Antonio Cubillo 1,2,* Estela Vega 1,2 Elena Garralda Rafael Alvarez Lisardo U. de la Varga Jesús R. Pascual Gema Sánchez 1,4 Francesca Sarno Susana H. Prieto 3 Sofía Perea Pedro P. Lopéz-Casas 4 Fernando López-Ríos and Manuel Hidalgo 4,5 1 Centro Integral Oncológico Clara Campal (CIOCC), Madrid, Spain 2 Universidad San Pablo CEU, Laboratorio Dianas Terapeúticas, Spanish National Cancer Research Centre (CNIO), 5 Beth Israel Deaconess Medical Center, Harvard...
The study goal was to examine the relationship between nab-paclitaxel delivery and SPARC (secreted protein acidic rich in cysteine) expression pancreatic tumor xenografts determine antistromal effect of nab-paclitaxel, which may affect vascular perfusion. SPARC-positive -negative mice bearing Panc02 (n = 5-6/group) were injected with IRDye 800CW (IR800)-labeled nab-paclitaxel. After 24 hours, tumors collected stained DL650-labeled anti-SPARC antibody, correlation distributions examined....
5003 Background: Understanding of the association between HRR mutations and outcomes in mCRPC pts is limited. This analysis investigated prevalence with/out (somatic and/or germline), stratified as BRCA, non-BRCA, or who initiated 1L treatment with novel hormonal therapy (NHT) taxane. Methods: Eligible from PROREPAIR-B (NCT03075735), PROSENZA (NCT02922218), PROSTAC (NCT02362620), PROSABI (NCT02787837) studies underwent paired somatic/germline DNA analyses using a custom NGS panel that...
<div>AbstractPurpose:<p>Pancreatic ductal adenocarcinoma (PDAC) has limited treatment options. We compared the efficacy of comprehensive precision medicine against that conventional in PDAC.</p>Patients and Methods:<p>We report a phase III trial advanced PDAC which patients were randomized (1:2) to treated at physician’s discretion (arm A) or B). Subjects arm B underwent tumor biopsy for whole-exome sequencing generate avatar mouse models patient-derived organoids...